Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1990 Aug;87(16):6465–6469. doi: 10.1073/pnas.87.16.6465

Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure.

M R Wilkins 1, S L Settle 1, P T Stockmann 1, P Needleman 1
PMCID: PMC54555  PMID: 2166956

Abstract

The effect of pharmacological manipulation of atriopeptin (AP) activity on sodium excretion and blood pressure was examined in the rat aortovenocaval (A-V) fistula model of cardiac failure. Introduction of an A-V shunt led to a marked and sustained elevation of plasma AP immunoreactivity and urinary cGMP levels. Further elevation of plasma AP levels by infusion of exogenous peptide induced modest increases in urinary sodium and cGMP excretion and a decrease in blood pressure but these responses were significantly attenuated compared to sham-operated animals. In contrast, low-dose infusion of M + B 22948 (a cGMP phosphodiesterase inhibitor) or thiorphan [a neutral endopeptidase (membrane metallo-endopeptidase, EC 3.4.24.11) inhibitor] induced a natriuresis in A-V fistula rats, which exceeded that seen in control animals given these compounds and matched the peak natriuresis produced in sham-operated animals by high doses of AP. In the doses used, these compounds had little effect on blood pressure. The greater renal efficacy of M + B 22948 in A-V fistula rats is consistent with postreceptor facilitation of AP activity. The effect of thiorphan on sodium excretion was accompanied by a pronounced increase in urinary cGMP and AP immunoreactivity excretion (and was attenuated by anti-AP monoclonal antibody) but could not be explained solely in terms of an increase in circulating AP levels. It is proposed that thiorphan allows filtered AP to reach renal tubule sites that are normally inaccessible to the peptide and are thus protected from down-regulation by high circulating AP levels. The implication of these observations for patients in cardiac failure is the potential for using pharmacological agents to maximize the response to endogenous AP without compromising cardiac function.

Full text

PDF
6465

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergstrand H., Kristoffersson J., Lundquist B., Schurmann A. Effects of antiallergic agents, compound 48/80, and some reference inhibitors on the activity of partially purified human lung tissue adenosine cyclic 3',5'-monophosphate and guanosine cyclic 3',5'-monophosphate phosphodiesterases. Mol Pharmacol. 1977 Jan;13(1):38–43. [PubMed] [Google Scholar]
  2. Blaine E. H. Atrial natriuretic factor plays a significant role in body fluid homeostasis. Hypertension. 1990 Jan;15(1):2–8. doi: 10.1161/01.hyp.15.1.2. [DOI] [PubMed] [Google Scholar]
  3. Burnett J. C., Jr, Kao P. C., Hu D. C., Heser D. W., Heublein D., Granger J. P., Opgenorth T. J., Reeder G. S. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986 Mar 7;231(4742):1145–1147. doi: 10.1126/science.2935937. [DOI] [PubMed] [Google Scholar]
  4. Chinkers M., Garbers D. L., Chang M. S., Lowe D. G., Chin H. M., Goeddel D. V., Schulz S. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature. 1989 Mar 2;338(6210):78–83. doi: 10.1038/338078a0. [DOI] [PubMed] [Google Scholar]
  5. Cody R. J., Atlas S. A., Laragh J. H., Kubo S. H., Covit A. B., Ryman K. S., Shaknovich A., Pondolfino K., Clark M., Camargo M. J. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986 Nov;78(5):1362–1374. doi: 10.1172/JCI112723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Crozier I. G., Nicholls M. G., Ikram H., Espiner E. A., Gomez H. J., Warner N. J. Haemodynamic effects of atrial peptide infusion in heart failure. Lancet. 1986 Nov 29;2(8518):1242–1245. doi: 10.1016/s0140-6736(86)92675-9. [DOI] [PubMed] [Google Scholar]
  7. Freeman R. H., Davis J. O., Vari R. C. Renal response to atrial natriuretic factor in conscious dogs with caval constriction. Am J Physiol. 1985 Apr;248(4 Pt 2):R495–R500. doi: 10.1152/ajpregu.1985.248.4.R495. [DOI] [PubMed] [Google Scholar]
  8. Garvin J. L. Inhibition of Jv by ANF in rat proximal straight tubules requires angiotensin. Am J Physiol. 1989 Nov;257(5 Pt 2):F907–F911. doi: 10.1152/ajprenal.1989.257.5.F907. [DOI] [PubMed] [Google Scholar]
  9. Gee N. S., Bowes M. A., Buck P., Kenny A. J. An immunoradiometric assay for endopeptidase-24.11 shows it to be a widely distributed enzyme in pig tissues. Biochem J. 1985 May 15;228(1):119–126. doi: 10.1042/bj2280119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hamet P., Tremblay J., Pang S. C., Skuherska R., Schiffrin E. L., Garcia R., Cantin M., Genest J., Palmour R., Ervin F. R. Cyclic GMP as mediator and biological marker of atrial natriuretic factor. J Hypertens Suppl. 1986 Jun;4(2):S49–S56. [PubMed] [Google Scholar]
  11. Huang C. L., Ives H. E., Cogan M. G. In vivo evidence that cGMP is the second messenger for atrial natriuretic factor. Proc Natl Acad Sci U S A. 1986 Oct;83(20):8015–8018. doi: 10.1073/pnas.83.20.8015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kohzuki M., Hodsman G. P., Johnston C. I. Attenuated response to atrial natriuretic peptide in rats with myocardial infarction. Am J Physiol. 1989 Feb;256(2 Pt 2):H533–H538. doi: 10.1152/ajpheart.1989.256.2.H533. [DOI] [PubMed] [Google Scholar]
  13. Lattion A. L., Michel J. B., Arnauld E., Corvol P., Soubrier F. Myocardial recruitment during ANF mRNA increase with volume overload in the rat. Am J Physiol. 1986 Nov;251(5 Pt 2):H890–H896. doi: 10.1152/ajpheart.1986.251.5.H890. [DOI] [PubMed] [Google Scholar]
  14. Light D. B., Schwiebert E. M., Karlson K. H., Stanton B. A. Atrial natriuretic peptide inhibits a cation channel in renal inner medullary collecting duct cells. Science. 1989 Jan 20;243(4889):383–385. doi: 10.1126/science.2463673. [DOI] [PubMed] [Google Scholar]
  15. McLaughlin L. L., Wei Y. F., Stockmann P. T., Leahy K. M., Needleman P., Grassi J., Pradelles P. Development, validation and application of an enzyme immunoassay (EIA) of atriopeptin. Biochem Biophys Res Commun. 1987 Apr 14;144(1):469–476. doi: 10.1016/s0006-291x(87)80533-8. [DOI] [PubMed] [Google Scholar]
  16. Morgan D. A., Peuler J. D., Koepke J. P., Mark A. L., DiBona G. F. Renal sympathetic nerves attenuate the natriuretic effects of atrial peptide. J Lab Clin Med. 1989 Nov;114(5):538–544. [PubMed] [Google Scholar]
  17. Olins G. M., Krieter P. A., Trapani A. J., Spear K. L., Bovy P. R. Specific inhibitors of endopeptidase 24.11 inhibit the metabolism of atrial natriuretic peptides in vitro and in vivo. Mol Cell Endocrinol. 1989 Feb;61(2):201–208. doi: 10.1016/0303-7207(89)90131-7. [DOI] [PubMed] [Google Scholar]
  18. Raine A. E., Erne P., Bürgisser E., Müller F. B., Bolli P., Burkart F., Bühler F. R. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med. 1986 Aug 28;315(9):533–537. doi: 10.1056/NEJM198608283150901. [DOI] [PubMed] [Google Scholar]
  19. Saito Y., Nakao K., Arai H., Nishimura K., Okumura K., Obata K., Takemura G., Fujiwara H., Sugawara A., Yamada T. Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart. J Clin Invest. 1989 Jan;83(1):298–305. doi: 10.1172/JCI113872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Saito Y., Nakao K., Nishimura K., Sugawara A., Okumura K., Obata K., Sonoda R., Ban T., Yasue H., Imura H. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation. 1987 Jul;76(1):115–124. doi: 10.1161/01.cir.76.1.115. [DOI] [PubMed] [Google Scholar]
  21. Seymour A. A., Smith S. G., 3rd, Mazack E. K. Effects of renal perfusion pressure on the natriuresis induced by atrial natriuretic factor. Am J Physiol. 1987 Aug;253(2 Pt 2):F234–F238. doi: 10.1152/ajprenal.1987.253.2.F234. [DOI] [PubMed] [Google Scholar]
  22. Stephenson S. L., Kenny A. J. The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J. 1987 Apr 1;243(1):183–187. doi: 10.1042/bj2430183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Trapani A. J., Smits G. J., McGraw D. E., Spear K. L., Koepke J. P., Olins G. M., Blaine E. H. Thiorphan, an inhibitor of endopeptidase 24.11, potentiates the natriuretic activity of atrial natriuretic peptide. J Cardiovasc Pharmacol. 1989 Sep;14(3):419–424. doi: 10.1097/00005344-198909000-00010. [DOI] [PubMed] [Google Scholar]
  24. Tremblay J., Gerzer R., Vinay P., Pang S. C., Béliveau R., Hamet P. The increase of cGMP by atrial natriuretic factor correlates with the distribution of particulate guanylate cyclase. FEBS Lett. 1985 Feb 11;181(1):17–22. doi: 10.1016/0014-5793(85)81105-4. [DOI] [PubMed] [Google Scholar]
  25. Waldman S. A., Rapoport R. M., Murad F. Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem. 1984 Dec 10;259(23):14332–14334. [PubMed] [Google Scholar]
  26. Wilkins M. R., Settle S. L., Needleman P. Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3',5'-cyclic monophosphate degradation. J Clin Invest. 1990 Apr;85(4):1274–1279. doi: 10.1172/JCI114564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Winaver J., Hoffman A., Burnett J. C., Jr, Haramati A. Hormonal determinants of sodium excretion in rats with experimental high-output heart failure. Am J Physiol. 1988 May;254(5 Pt 2):R776–R784. doi: 10.1152/ajpregu.1988.254.5.R776. [DOI] [PubMed] [Google Scholar]
  28. Wong K. R., Xie M. H., Shi L. B., Liu F. Y., Huang C. L., Gardner D. G., Cogan M. G. Urinary cGMP as biological marker of the renal activity of atrial natriuretic factor. Am J Physiol. 1988 Dec;255(6 Pt 2):F1220–F1224. doi: 10.1152/ajprenal.1988.255.6.F1220. [DOI] [PubMed] [Google Scholar]
  29. Yasue H., Obata K., Okumura K., Kurose M., Ogawa H., Matsuyama K., Jougasaki M., Saito Y., Nakao K., Imura H. Increased secretion of atrial natriuretic polypeptide from the left ventricle in patients with dilated cardiomyopathy. J Clin Invest. 1989 Jan;83(1):46–51. doi: 10.1172/JCI113883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Zeidel M. L., Silva P., Brenner B. M., Seifter J. L. cGMP mediates effects of atrial peptides on medullary collecting duct cells. Am J Physiol. 1987 Mar;252(3 Pt 2):F551–F559. doi: 10.1152/ajprenal.1987.252.3.F551. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES